Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.34 |
| ▸ | PPARG | P37231 | 4/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280090 | 0.93 | SMN1; SMN2 (0.39) | POLBSMN1; SMN2RXFP1PPARGPPARA | |
| SCHEMBL16280381 | 0.90 | SMN1; SMN2 (0.38) | POLBSMN1; SMN2RXFP1SCN9ATP53 | |
| SCHEMBL16280258 | 0.89 | SMN1; SMN2 (0.39) | POLBSMN1; SMN2RXFP1SCN9ATP53 | |
| SCHEMBL16280566 | 0.89 | SMN1; SMN2 (0.39) | POLBSMN1; SMN2RXFP1SCN9ATP53 | |
| SCHEMBL16280426 | 0.88 | SMN1; SMN2 (0.41) | POLBSMN1; SMN2RXFP1SCN9ATP53 | |
| SCHEMBL16279902 | 0.87 | SMN1; SMN2 (0.39) | POLBSMN1; SMN2RXFP1SCN9ATP53 | |
| SCHEMBL16279928 | 0.86 | PPARG (0.38) | POLBSMN1; SMN2RXFP1NPY5RPPARG | |
| SCHEMBL16280448 | 0.85 | PPARG (0.37) | POLBSMN1; SMN2RXFP1NPY5RPPARG | |
| SCHEMBL16280372 | 0.85 | SMN1; SMN2 (0.42) | POLBSMN1; SMN2RXFP1SCN9ATP53 | |
| SCHEMBL16280203 | 0.83 | SMN1; SMN2 (0.41) | POLBSMN1; SMN2RXFP1SCN9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10211414-B2 | Phosphorescent tetradentate metal complexes having modified emission spectra | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170331056-A1 | PHOSPHORESCENT TETRADENTATE METAL COMPLEXES HAVING MODIFIED EMISSION SPECTRA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-11-16 | — | — | US | disclosed |
| US-9673409-B2 | Phosphorescent tetradentate metal complexes having modified emission spectra | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2015027060-A1 | PHOSPHORESCENT TETRADENTATE METAL COMPLEXES HAVING MODIFIED EMISSION SPECTRA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20140364605-A1 | PHOSPHORESCENT TETRADENTATE METAL COMPLEXES HAVING MODIFIED EMISSION SPECTRA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170331056-A1 | PHOSPHORESCENT TETRADENTATE METAL COMPLEXES HAVING MODIFIED EMISSION SPECTRA | AP2S1, PICALM, TRPC3 | POLB 2889/4885SMN1; SMN2 2678/4885RXFP1 4793/4885 |
| US-10211414-B2 | Phosphorescent tetradentate metal complexes having modified emission spectra | AP2S1, PICALM, TRPC3 | POLB 2889/4885SMN1; SMN2 2678/4885RXFP1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.